Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review

References

• Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis. 2005;191(Suppl 1):S97–106.
   PubMedGoogle Scholar
• Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(Rr–2):1–24.
   PubMedGoogle Scholar
• Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–265.
   PubMed Web of Science ®Google Scholar
• Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst. 1999;91(6):506–511.
   PubMedGoogle Scholar
• De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124(7):1626–1636.
   PubMed Web of Science ®Google Scholar
• Backes DM, Kurman RJ, Pimenta JM, et al. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009;20(4):449–457.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467–475.
   PubMed Web of Science ®Google Scholar
• De Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056.
   PubMed Web of Science ®Google Scholar
• Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–935.
   PubMed Web of Science ®Google Scholar
• Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–814.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–1943.
   PubMed Web of Science ®Google Scholar
• Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–1927.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen O-E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England J Med. 2015;372(8):711–723.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453–63.
   PubMed Web of Science ®Google Scholar
• Garnett GP, Waddell HC. Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol. 2000;19(1–2):101–111.
   PubMed Web of Science ®Google Scholar
• Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology. 2002;13(6):631–639.
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96(8):604–615.
   PubMed Web of Science ®Google Scholar
• Garnett GP, Kim JJ, French K, et al. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006;24(Suppl 3):S3/178–86.
   Google Scholar
• Pink J, Parker B, Petrou S. Cost effectiveness of HPV vaccination: a systematic review of modelling approaches. PharmacoEconomics. 2016;34(9):847–861.
   PubMed Web of Science ®Google Scholar
• Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics. 2009;12(5–6):343–351.
   PubMed Web of Science ®Google Scholar
• Jit M, Brisson M, Portnoy A, et al. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2(7):e406–14.
   PubMed Web of Science ®Google Scholar
• Seto K, Marra F, Raymakers A, et al. The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs. 2012;72(5):715–743.
   PubMed Web of Science ®Google Scholar
• Jeurissen S, Makar A. Epidemiological and economic impact of human papillomavirus vaccines. Int J Gynecol Cancer. 2009;19(4):761–771.
   PubMed Web of Science ®Google Scholar
• Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine. 2010;28(33):5473–5484.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, et al. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14(2):244–251.
   PubMed Web of Science ®Google Scholar
• Chandra A, Mosher WD, Copen C, et al. Sexual behavior, sexual attraction, and sexual identity in the United States: data from the 2006-2008 National Survey of Family Growth. Natl Health Stat Report. 2011;36:1–36.
   PubMedGoogle Scholar
• Mercer CH, Tanton C, Prah P, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). The Lancet. 2013;382(9907):1781–1794.
   PubMed Web of Science ®Google Scholar
• Brisson M, van de Velde N, Franco EL, et al. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis. 2011;204(3):372–376.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morbidity and Mortality Weekly Report. 2010;59(20):626–629.
   PubMedGoogle Scholar
• Nature Biotechnology. Flogging gardasil. Nat Biotech. 2007;25(3):261.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):630–632.
   PubMedGoogle Scholar
• Brotherton JML, Giuliano AR, Markowitz LE, et al. Monitoring the impact of HPV vaccine in males—considerations and challenges. Papillomavirus Res. 2016;2:106–111.
   PubMed Web of Science ®Google Scholar
• Zimet GD, Rosenthal SL. HPV vaccine and males: issues and challenges. Gynecol Oncol. 2010;117(2, Supplement):S26–S31.
   PubMed Web of Science ®Google Scholar
• The Lancet. GAVI injects new life into HPV vaccine rollout. The Lancet. 2013;381(9879):1688.
   Web of Science ®Google Scholar
• Canfell K, Chesson H, Kulasingam SL, et al. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30(Suppl 5):F157–67.
   PubMedGoogle Scholar
• Smith MA, Lew JB, Walker RJ, et al. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine. 2011;29(48):9112–9122.
   PubMed Web of Science ®Google Scholar
• Brisson M, Benard E, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8–e17.
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Disease Journal. 2007;13(1):28.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Brisson M, Edmunds WJ, et al. Modeling cervical cancer prevention in developed countries. Vaccine. 2008;26, (Supplement 10):K76–K86.
   PubMedGoogle Scholar
• Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10(11):1915–1923.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29(46):8443–8450.
   PubMed Web of Science ®Google Scholar
• Van Effelterre TP, Hogea C, Taylor SM. Projected impact of cervarix vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom. Hum Vaccin Immunother. 2016;12(1):8–19.
   PubMed Web of Science ®Google Scholar
• Pearson AL, Kvizhinadze G, Wilson N, et al. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program. BMC Infect Dis. 2014;14:351.
   PubMed Web of Science ®Google Scholar
• Laprise JF, Drolet M, Boily MC, et al. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine. 2014;32(44):5845–5853.
   PubMed Web of Science ®Google Scholar
• Burger EA, Sy S, Nygård M, et al. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PLoS ONE. 2014;9(3):e89974.
   PubMed Web of Science ®Google Scholar
• Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337:a769.
   Google Scholar
• Luyten J, Engelen B, Beutels P. The sexual ethics of HPV vaccination for boys. HEC Forum. 2014;26(1):27–42.
   PubMedGoogle Scholar
• Prue G. Human papillomavirus: a strong case for vaccinating boys. Trends in Urology & Men’s Health. 2016;7(1):7–11.
   Google Scholar
• Baussano I, Dillner J, Lazzarato F, et al. Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect Agent Cancer. 2014;9:4.
   PubMed Web of Science ®Google Scholar
• Smith MA, Canfell K, Brotherton JM, et al. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer. 2008;123(8):1854–1863.
   PubMed Web of Science ®Google Scholar
• Choi YH, Jit M, Gay N, et al. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine. 2010;28(24):4091–4102.
   PubMed Web of Science ®Google Scholar
• Elfstrom KM, Lazzarato F, Franceschi S, et al. Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs. J Infect Dis. 2016;213(2):199–205.
   PubMed Web of Science ®Google Scholar
• Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270–280.
   PubMed Web of Science ®Google Scholar
• Kim JJ. A cost-effectiveness analysis of targeted HPV vaccination of men who have sex with men in the United States. Lancet Infect Dis. 2010;10(12):845–852.
   PubMed Web of Science ®Google Scholar
• Lin A, Ong KJ, Hobbelen P, et al. Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clin Infect Dis. 2017;64(5):580–588.
   PubMed Web of Science ®Google Scholar
• Qendri V, Bogaards JA, Berkhof J. Health and economic impact of a tender-based, sex-neutral human papillomavirus 16/18 vaccination program in the Netherlands. J Infect Dis. 2017;216(2):210–219.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. New England J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males–advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705–1708.
   PubMedGoogle Scholar
• National HPV Vaccination Program Register. HPV Vaccination Coverage by Dose 2011 2017 [updated 2017 Nov; cited 2018 Apr 17]. Available from: http://www.hpvregister.org.au/research/coverage-data/hpv-vaccination-coverage-by-dose-2011
   Google Scholar
• Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.
   Google Scholar
• Chow EPF, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. 2017;17(1):68–77.
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Benefits Advisory Committee. Public Summary Document. Quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine, solution for injection, 0.5 mL, solution for injection pre-filled syringe single dose, Gardasil®––November 2011 2011 [updated 2012 Mar 02; cited 2018 Apr 04]. Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-11/pbac-psd-quadrivalent-nov11
   Google Scholar
• Prah P, Copas AJ, Mercer CH, et al. Patterns of sexual mixing with respect to social, health and sexual characteristics among heterosexual couples in England: analyses of probability sample survey data. Epidemiol Infect. 2015;143(7):1500–1510.
   PubMed Web of Science ®Google Scholar
• Jepsen LK, Jepsen CA. An empirical analysis of the matching patterns of same-sex and opposite-sex couples. Demography. 2002;39(3):435–453.
   PubMed Web of Science ®Google Scholar
• Hamilton DT, Morris M. The racial disparities in STI in the U.S.: concurrency, STI prevalence, and heterogeneity in partner selection. Epidemics. 2015;11:56–61.
   PubMed Web of Science ®Google Scholar
• Malagón T, Burchell A, El-Zein M, et al. Assortativity and mixing by sexual behaviors and sociodemographic characteristics in young adult heterosexual dating partnerships. Sex Transm Dis. 2017;44(6):329–337.
   PubMed Web of Science ®Google Scholar
• Rosenfeld MJ. Racial, educational and religious endogamy in the United States: a comparative historical perspective. Soc Forces. 2008;87(1):1–31.
   Web of Science ®Google Scholar
• Bohl DD, McFarland W, Raymond HF. Improved measures of racial mixing among men who have sex with men using Newman’s assortativity coefficient. Sex Transm Infect. 2011;87(7):616–620.
   PubMed Web of Science ®Google Scholar
• Blackwell DL, Lichter DT. Homogamy among dating, cohabiting, and married couples. Sociological Q. 2004;45(4):719–737.
   Web of Science ®Google Scholar
• Garnett GP, Hughes JP, Anderson RM, et al. Sexual mixing patterns of patients attending sexually transmitted diseases clinics. Sex Transm Dis. 1996;23(3):248–257.
   PubMed Web of Science ®Google Scholar
• Doherty IA, Schoenbach VJ, Adimora AA. Sexual mixing patterns and heterosexual HIV transmission among African Americans in the Southeastern United States. J Acquir Immune Defic Syndr. 2009;52(1):114–120.
   PubMed Web of Science ®Google Scholar
• Darroch JE, Landry DJ, Oslak S. Age differences between sexual partners in the United States. Fam Plann Perspect. 1999;31(4):160–167.
   PubMedGoogle Scholar
• Mercer CH, Copas AJ, Sonnenberg P, et al. Who has sex with whom? Characteristics of heterosexual partnerships reported in a national probability survey and implications for STI risk. Int J Epidemiol. 2009;38(1):206–214.
   PubMed Web of Science ®Google Scholar
• Vänskä S, Auranen K, Leino T, et al. Impact of vaccination on 14 high-risk hpv type infections: a mathematical modelling approach. PLoS ONE. 2013;8(8):e72088.
   PubMed Web of Science ®Google Scholar
• Schwartz CR, Graf NL. Assortative matching among same-sex and different-sex couples in the United States, 1990-2000. Demogr Res. 2009;21:843–878.
   PubMed Web of Science ®Google Scholar
• Benard VB, Johnson CJ, Thompson TD, et al. Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer. 2008;113(10 Suppl):2910–2918.
   PubMed Web of Science ®Google Scholar
• Khan MJ, Partridge EE, Wang SS, et al. Socioeconomic status and the risk of cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer. 2005;104(1):61–70.
   PubMed Web of Science ®Google Scholar
• Marrett LD, Chaudhry M. Cancer incidence and mortality in Ontario First Nations, 1968-1991 (Canada). Cancer Causes Control. 2003;14(3):259–268.
   PubMed Web of Science ®Google Scholar
• Singh GK, Miller BA, Hankey BF, et al. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer. 2004;101(5):1051–1057.
   PubMed Web of Science ®Google Scholar
• Jensen KE, Hannibal CG, Nielsen A, et al. Social inequality and incidence of and survival from cancer of the female genital organs in a population-based study in Denmark, 1994-2003. Eur J Cancer. 2008;44(14):2003–2017.
   PubMed Web of Science ®Google Scholar
• Malagon T, Drolet M, Boily MC, et al. Changing inequalities in cervical cancer: modeling the impact of vaccine uptake, vaccine herd effects, and cervical cancer screening in the post-vaccination era. Cancer Epidemiol Biomarkers Prev. 2015;24(1):276–285.
   PubMed Web of Science ®Google Scholar
• Shafer LA, Jeffrey I, Elias B, et al. Quantifying the impact of dissimilar HPV vaccination uptake among Manitoban school girls by ethnicity using a transmission dynamic model. Vaccine. 2013;31(42):4848–4855.
   PubMed Web of Science ®Google Scholar
• Crowcroft NS, Hamid JS, Deeks SL, et al. Human papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation study. BMC Public Health. 2012;12:935.
   PubMed Web of Science ®Google Scholar
• Johnson HC, Lafferty EI, Eggo RM, et al. Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study. Lancet Public Health. 2018;3(1):e44–e51.
   PubMed Web of Science ®Google Scholar
• Smith C, Ding L, Gorbach P, et al. Who's not protected in the herd? Factors associated with vaccine-type HPV in unvaccinated women. J Pediatr Adolesc Gynecol. 2018;31(2):89–93.
   Google Scholar
• Smith MA, Liu B, McIntyre P, et al. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis. 2015;211(1):91–99.
   PubMed Web of Science ®Google Scholar
• Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years––United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(33):850–858.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Soderlund-Strand A, Vanska S, et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-results of a community-randomized clinical trial (I). Int J Cancer. 2018;142(5):949–958.
   PubMed Web of Science ®Google Scholar
• Durham DP, Ndeffo-Mbah ML, Skrip LA, et al. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. Proc Natl Acad Sci U S A. 2016;113(18):5107–5112.
   PubMed Web of Science ®Google Scholar
• Riesen M, Garcia V, Low N, et al. Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland. Vaccine. 2017;35(52):7312–7321.
   PubMed Web of Science ®Google Scholar
• Tanton C, Johnson AM, Macdowall W, et al. Forming new sex partnerships while overseas: findings from the third British National Survey of Sexual Attitudes & Lifestyles (Natsal-3). Sex Transm Infect. 2016;92(6):415–423.
   PubMed Web of Science ®Google Scholar
• Larsen LJ, Walters NP. Married-couple households by nativity status: 2011. American Community Survey Briefs: United States Census Bureau, Washington, DC; 2013.
   Google Scholar
• van Tubergen F, Maas I. Ethnic intermarriage among immigrants in the Netherlands: an analysis of population data. Soc Sci Res. 2007;36(3):1065–1086.
   Web of Science ®Google Scholar
• Qian Z, Lichter DT. Measuring marital assimilation: intermarriage among natives and immigrants. Soc Sci Res. 2001;30(2):289–312.
   Web of Science ®Google Scholar
• Hachey KJ, Allen RH, Nothnagle M, et al. Requiring human papillomavirus vaccine for immigrant women. Obstet Gynecol. 2009;114(5):1135–1139.
   PubMed Web of Science ®Google Scholar
• Fernández de Casadevante V, Cantarero-Arévalo L, Cuesta JG, et al. Ethnic background and human papillomavirus vaccine uptake in Denmark: a countrywide retrospective cohort study including 274,154 women aged 19–28 years. Papillomavirus Res. 2016;2:78–84.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Dunne EF, Hariri S, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–664.
   PubMed Web of Science ®Google Scholar
• Kim S, Arduino JM, Roberts CC, et al. Incidence and predictors of human papillomavirus-6, −11, −16, and −18 infection in young Norwegian women. Sex Transm Dis. 2011;38(7):587–597.
   PubMed Web of Science ®Google Scholar
• Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis. 2007;196(8):1128–1136.
   PubMed Web of Science ®Google Scholar
• Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. New England J Med. 2006;354(25):2645–2654.
   PubMed Web of Science ®Google Scholar
• Moscicki A, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. Jama. 2001;285(23):2995–3002.
   PubMed Web of Science ®Google Scholar
• Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190(12):2077–2087.
   PubMed Web of Science ®Google Scholar
• Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ. 2000;163(5):503–508.
   Google Scholar
• Chow EP, Read TR, Law MG, et al. Assortative sexual mixing patterns in male–female and male–male partnerships in Melbourne, Australia: implications for HIV and sexually transmissible infection transmission. Sex Health. 2016;13(5):451–456.
   PubMed Web of Science ®Google Scholar
• Burchell AN, Rodrigues A, Moravan V, et al. Determinants of prevalent human papillomavirus in recently formed heterosexual partnerships: a dyadic-level analysis. J Infect Dis. 2014;210(6):846–852.
   PubMed Web of Science ®Google Scholar
• Malagon T, Joumier V, Boily MC, et al. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis. Vaccine. 2013;31(13):1740–1747.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016.
   Web of Science ®Google Scholar
• Mollers M, Lubbers K, Spoelstra SK, et al. Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands. BMC Public Health. 2014;14(1):288.
   PubMedGoogle Scholar
• Liddon NC, Leichliter JS, Markowitz LE. Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med. 2012;42(1):44–52.
   PubMed Web of Science ®Google Scholar
• Sonnenberg P, Clifton S, Beddows S, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). The Lancet. 2013;382(9907):1795–1806.
   PubMed Web of Science ®Google Scholar
• Wymann MN, Zographos AS, Altpeter E, et al. Human papillomavirus vaccine uptake in adolescence and adherence to cervical cancer screening in Switzerland: a national cross-sectional survey. Int J Public Health. 2018;63(1):105–114.
   PubMed Web of Science ®Google Scholar
• Baussano I, Lazzarato F, Ronco G, et al. Different challenges in eliminating hpv16 compared to other types: a modeling study. J Infect Dis. 2017;216(3):336–344.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(Rr–13):1–25.
   Google Scholar
• Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev. 1993;15(2):265–302.
   PubMed Web of Science ®Google Scholar
• Katz SL, King K, Varughese P, et al. Measles elimination in Canada. J Infect Dis. 2004;189(Supplement_1):S236–S242.
   PubMedGoogle Scholar
• Grant GB, Reef SE, Patel M, et al. Progress in rubella and congenital rubella syndrome control and elimination––worldwide, 2000-2016. MMWR Morb Mortal Wkly Rep. 2017;66(45):1256–1260.
   PubMed Web of Science ®Google Scholar
• Garnett GP, Anderson RM. Sexually transmitted diseases and sexual behavior: insights from mathematical models. J Infect Dis. 1996;174(Suppl 2):S150–61.
   PubMedGoogle Scholar
• Brisson M, Van de Velde N, Boily MC. Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. Sex Transm Infect. 2011;87(1):41–43.
   PubMed Web of Science ®Google Scholar
• Bogaards JA, Coupe VM, Xiridou M, et al. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology. 2011;22(4):505–515.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377(9769):932–940.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Perez G, Wheeler CM, et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1585–1594.
   PubMed Web of Science ®Google Scholar
• Jaisamrarn U, Castellsague X, Garland SM, et al. Natural history of progression of hpv infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One. 2013;8(11):e79260.
   PubMed Web of Science ®Google Scholar
• Rositch AF, Koshiol J, Hudgens MG, et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer. 2013;133(6):1271–1285.
   PubMed Web of Science ®Google Scholar
• Korostil IA, Ali H, Guy RJ, et al. Near elimination of genital warts in australia predicted with extension of human papillomavirus vaccination to males. Sex Transm Dis. 2013;40(11):833–835.
   PubMed Web of Science ®Google Scholar
• Chow EP, Read TR, Wigan R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91(3):214–219.
   PubMed Web of Science ®Google Scholar
• LaMontagne DS, Bloem PJN, Brotherton JML, et al. Progress in HPV vaccination in low- and lower-middle-income countries. Int J Gynecol Obstetrics. 2017;138:7–14.
   PubMed Web of Science ®Google Scholar
• Tota JE, Ramanakumar AV, Jiang M, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol. 2013;178(4):625–634.
   PubMed Web of Science ®Google Scholar
• Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–580.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241–268.
   PubMedGoogle Scholar
• Dillner J, Arbyn M, Unger E, et al. Monitoring of human papillomavirus vaccination. Clin Exp Immunol. 2011;163(1):17–25.
   PubMed Web of Science ®Google Scholar
• Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006-2014. Am J Public Health. 2018;108(1):112–119.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Legler A, Hanchate A. Trends in male and female genital warts among adolescents in a safety-net health care system 2004-2013: correlation with introduction of female and male human papillomavirus vaccination. Sex Transm Dis. 2015;42(12):665–668.
   PubMed Web of Science ®Google Scholar
• Cameron RL, Kavanagh K, Pan J, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerg Infect Dis. 2016;22(1):56–64.
   PubMed Web of Science ®Google Scholar
• Baandrup L, Blomberg M, Dehlendorff C, et al. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013;40(2):130–135.
   PubMed Web of Science ®Google Scholar
• Sando N, Kofoed K, Zachariae C, et al. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women–an ecological study. Acta Derm Venereol. 2014;94(3):288–292.
   PubMed Web of Science ®Google Scholar
• Mesher D, Panwar K, Thomas SL, et al. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open. 2016;6:2.
   Web of Science ®Google Scholar
• Baldur-Felskov B, Dehlendorff C, Junge J, et al. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control. 2014;25(7):915–922.
   PubMed Web of Science ®Google Scholar
• Oliver SE, Unger ER, Lewis R, et al. Prevalence of human papillomavirus among females after vaccine introduction-National Health and Nutrition Examination Survey, United States, 2003-2014. J Infect Dis. 2017;216(5):594–603.
   PubMed Web of Science ®Google Scholar
• Tanton C, Mesher D, Beddows S, et al. Human papillomavirus (HPV) in young women in Britain: population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017;3:36–41.
   PubMed Web of Science ®Google Scholar
• Stupiansky NW, Zimet GD, Cummings T, et al. Accuracy of self-reported hpv vaccine receipt among adolescent girls and their mothers. J Adolescent Health: Official Publication Soc Adolesc Med. 2012;50(1):103–105.
   PubMed Web of Science ®Google Scholar
• Dunne EF, Naleway A, Smith N, et al. Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated us healthcare delivery system in 2007 and 2012-2013. J Infect Dis. 2015;212(12):1970–1975.
   PubMed Web of Science ®Google Scholar
• Berenson AB, Hirth JM, Chang M. Change in human papillomavirus prevalence among U.S. women aged 18–59 Years, 2009-2014. Obstet Gynecol. 2017;130(4):693–701.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208(3):385–393.
   PubMed Web of Science ®Google Scholar
• Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130(2):e249–56.
   PubMed Web of Science ®Google Scholar
• Kahn JA, Widdice LE, Ding L, et al. Substantial decline in vaccine-type Human Papillomavirus (HPV) among vaccinated young women during the first 8 Years after HPV vaccine introduction in a community. Clin Infect Dis. 2016;63(10):1281–1287.
   PubMed Web of Science ®Google Scholar
• Tarney CM, Klaric J, Beltran T, et al. Prevalence of human papillomavirus in self-collected cervicovaginal swabs in young women in the United States between 2003 and 2012. Obstet Gynecol. 2016;128(6):1241–1247.
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293–1302.
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206(11):1645–1651.
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JML, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14(10):958–966.
   PubMed Web of Science ®Google Scholar
• Benard VB, Castle PE, Jenison SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol. 2017;3(6):833–837.
   PubMed Web of Science ®Google Scholar
• Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health. 2012;102(5):833–835.
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085–2092.
   PubMed Web of Science ®Google Scholar
• Thone K, Horn J, Mikolajczyk R. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data. BMC Infect Dis. 2017;17(1):564.
   PubMedGoogle Scholar
• Dominiak-Felden G, Gobbo C, Simondon F. Evaluating the early benefit of quadrivalent hpv vaccine on genital warts in Belgium: a cohort study. PLoS One. 2015;10(7):e0132404.
   PubMed Web of Science ®Google Scholar
• Canvin M, Sinka K, Hughes G, et al. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect. 2017;93(2):125–128.
   PubMed Web of Science ®Google Scholar
• Cocchio S, Baldovin T, Bertoncello C, et al. Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. BMC Infect Dis. 2017;17(1):249.
   PubMedGoogle Scholar
• Kirby T. Australia to be first country to vaccinate boys against HPV. Lancet Oncol. 2012;13(8):e333.
   PubMed Web of Science ®Google Scholar
• Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009;85(7):499–502.
   PubMed Web of Science ®Google Scholar
• Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11(1):39–44.
   PubMed Web of Science ®Google Scholar
• Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87(7):544–547.
   PubMed Web of Science ®Google Scholar
• Lurie S, Mizrachi Y, Chodick G, et al. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure. Gynecol Oncol. 2017;146(2):299–304.
   PubMed Web of Science ®Google Scholar
• Steben M, Ouhoummane N, Rodier C, et al. The early impact of human papillomavirus vaccination on anogenital warts in Quebec, Canada. J Med Virol. 2018;90(3):592–598.
   PubMed Web of Science ®Google Scholar
• Pillsbury AJ, Quinn HE, Evans TD, et al. Population-level herd protection of males from a female human papillomavirus vaccination program: evidence from Australian Serosurveillance. Clin Infect Dis. 2017;65(5):827–832.
   PubMed Web of Science ®Google Scholar
• Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012;206(6):860–866.
   PubMed Web of Science ®Google Scholar
• Soderlund-Strand A, Uhnoo I, Dillner J. Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2757–2764.
   PubMed Web of Science ®Google Scholar
• Tota JE, Ramana-Kumar AV, El-Khatib Z, et al. The road ahead for cervical cancer prevention and control. Curr Oncol. 2014;21(2):e255–64.
   PubMed Web of Science ®Google Scholar
• Rogstad KE. The psychological impact of abnormal cytology and colposcopy. Bjog. 2002;109(4):364–368.
   PubMed Web of Science ®Google Scholar
• Cotton S, Sharp L, Cochran C, et al. After-effects reported by women having follow-up cervical cytology tests in primary care: a cohort study within the TOMBOLA trial. Br J Gen Pract. 2011;61(587):e333–9.
   PubMed Web of Science ®Google Scholar
• Sharp L, Cotton S, Cochran C, et al. After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. Bjog. 2009;116(11):1506–1514.
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016;354:i3633.
   Google Scholar
• Franco EL, Mahmud SM, Tota J, et al. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res. 2009;40(6):478–485.
   PubMed Web of Science ®Google Scholar
• El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none. J Clin Virol. 2016;76(Suppl 1):S62–8.
   PubMedGoogle Scholar
• Palmer TJ, McFadden M, Pollock KG, et al. HPV immunisation and cervical screening–confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study. Br J Cancer. 2016;114(5):582–589.
   PubMed Web of Science ®Google Scholar
• Pedersen K, Burger EA, Nygård M, et al. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines. Eur J Cancer. 2018;91:68–75.
   PubMed Web of Science ®Google Scholar
• Heard I, Tondeur L, Arowas L, et al. Effectiveness of human papillomavirus vaccination on prevalence of vaccine genotypes in young sexually active women in France. J Infect Dis. 2017;215(5):757–763.
   PubMed Web of Science ®Google Scholar
• Naber SK, Matthijsse SM, Rozemeijer K, et al. Cervical cancer screening in partly hpv vaccinated cohorts – a cost-effectiveness analysis. Plos One. 2016;11(1):e0145548.
   PubMed Web of Science ®Google Scholar
• Giorgi Rossi P, Carozzi F, Federici A, et al. Cervical cancer screening in women vaccinated against human papillomavirus infection: recommendations from a consensus conference. Prev Med. 2017;98:21–30.
   PubMed Web of Science ®Google Scholar
• Vink MA, Bogaards JA, van Kemenade FJ, et al. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013;178(7):1161–1169.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Robles C, Diaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016;13(2):119–132.
   PubMed Web of Science ®Google Scholar
• Drolet M, Laprise JF, Brotherton JML, et al. The impact of human papillomavirus catch-up vaccination in Australia: implications for introduction of multiple age cohort vaccination and postvaccination data interpretation. J Infect Dis. 2017;216(10):1205–1209.
   PubMed Web of Science ®Google Scholar
• Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105(1):28–37.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16(10):1154–1168.
   PubMed Web of Science ®Google Scholar
• Burger EA, Kim JJ, Sy S, et al. Age of acquiring causal human papillomavirus (HPV) infections: leveraging simulation models to explore the natural history of HPV-induced cervical cancer. Clin Infect Dis. 2017;65(6):893–899.
   PubMed Web of Science ®Google Scholar
• Westra TA, Rozenbaum MH, Rogoza RM, et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis. 2011;204(3):377–384.
   PubMed Web of Science ®Google Scholar
• Bogaards JA, Coupe VM, Meijer CJ, et al. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine. 2011;29(48):8929–8936.
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Largeron N, Elbasha EH. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev Pharmacoecon Outcomes Res. 2008;8(5):491–500.
   PubMedGoogle Scholar
• Burger EA, Sy S, Nygard M, et al. Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway. J Infect Dis. 2015;211(2):206–215.
   PubMed Web of Science ®Google Scholar
• Turner HC, Baussano I, Garnett GP. Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine. Plos One. 2013;8(9):e75552.
   PubMed Web of Science ®Google Scholar
• Simms KT, Smith MA, Lew JB, et al. Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. Int J Cancer. 2016;139(12):2771–2780.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Burger EA, Sy S, et al. Optimal cervical cancer screening in women vaccinated against human papillomavirus. J Natl Cancer Inst. 2017;109:2.
   PubMedGoogle Scholar